Crystalline form
    10.
    发明申请
    Crystalline form 失效
    结晶形式

    公开(公告)号:US20060124049A1

    公开(公告)日:2006-06-15

    申请号:US10537645

    申请日:2003-12-04

    IPC分类号: H01L21/322

    CPC分类号: C07D409/12

    摘要: The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

    摘要翻译: 本发明包括(E)-2-(5-氯噻吩-2-基)-N - {(3S)-1 - [(1S)-1-甲基-2-吗啉-4-基-2-氧代乙基] -2-氧代吡咯烷-3-基)乙烯磺酰胺,其药物制剂,其制备方法及其在医药中的用途,特别用于改善指定因子Xa抑制剂的临床病症。